{"ticker": {"uuid": "884cf200-975c-4794-9716-89ea6c0b7fab", "symbol": "TBPH", "name": "Theravance Biopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has increased its price target for Theravance Biopharma (TBPH) shares to $17.00, up from the previous target of $15.00. This adjustment reflects an updated outlook on the company's valuation.", "url": "https://www.moomoo.com/news/post/72584556/theravance-biopharma-price-target-raised-to-17-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-07T17:10:51", "published_display": "07 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future", "summary": "Zymeworks is strategically pivoting beyond its oncology focus with the $929 million acquisition of Theravance Biopharma, gaining the FDA-approved COPD therapy, Yupelri. This move aligns with current biopharma M&A trends emphasizing de-risked, cash-generating assets to address pat", "url": "https://www.kavout.com/market-lens/zymeworks-929-million-pivot-how-a-copd-acquisition-redefines-its-future", "source_name": "Kavout | AI", "published_at": "2026-07-06T08:41:47", "published_display": "06 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Options", "summary": "This article provides a detailed financial overview of Theravance Biopharma Inc. (TBPH), including its latest stock performance, market capitalization, key financial ratios, and insider/institutional ownership data. It presents various metrics such as P/E, sales growth, profit ma", "url": "https://finviz.com/stock?t=TBPH&ty=oc&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-06T08:41:47", "published_display": "06 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI\u00ae extending generic availability to 2", "url": "https://www.stocktitan.net/sec-filings/TBPH/page-3.html", "source_name": "Stock Titan", "published_at": "2026-07-04T02:40:15", "published_display": "04 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Short Interest", "summary": "This article provides a detailed overview of Theravance Biopharma Inc (TBPH) stock, focusing on various financial metrics, short interest data, and performance indicators. It includes information on the company's market capitalization, income, sales, P/E ratio, short interest per", "url": "https://finviz.com/stock?t=TBPH&ta=1&p=d&ty=si&b=1", "source_name": "Finviz", "published_at": "2026-07-02T20:11:25", "published_display": "02 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Latest SEC Filings", "summary": "This article provides detailed financial data and performance metrics for Theravance Biopharma Inc (TBPH), including its latest stock close, market capitalization, income, sales, and various financial ratios. It also outlines insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=TBPH&ty=lf&page=36", "source_name": "Finviz", "published_at": "2026-07-02T19:40:54", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT", "summary": "Theravance Biopharma has announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, totaling approximately $929 million in equity value. In addition to the cash payment, Theravance Biopharma shareholders will receive a contingent value right (CVR) ", "url": "https://finance.yahoo.com/healthcare/articles/theravance-biopharma-enters-definitive-agreement-100000053.html", "source_name": "Market source", "published_at": "2026-07-02T09:41:16", "published_display": "02 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/theravance-biopharma-insider-sold-shares-082329638.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:23:29+00:00", "published_display": "02 Jul 2026 08:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales", "summary": "Funds associated with Eli Samaha, managed by Madison Avenue Partners, LP, have significantly reduced their stake in Theravance Biopharma (TBPH) through open-market sales. Over three days, the funds sold a total of 336,697 shares at weighted average prices around $17 per share. De", "url": "https://www.stocktitan.net/sec-filings/TBPH/form-4-theravance-biopharma-inc-insider-trading-activity-7e4ffd5226ae.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:13", "published_display": "01 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma in deal worth $929m", "summary": "Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition a", "url": "https://pmlive.com/pharma_news/zymeworks-to-acquire-theravance-biopharma-in-deal-worth-929m/", "source_name": "PMLiVE", "published_at": "2026-07-01T09:39:40", "published_display": "01 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks", "summary": "Arthur Cox advised Theravance Biopharma, Inc. on its definitive agreement to be acquired by Zymeworks Inc. for approximately US$929 million. The transaction values Theravance Biopharma at US$17.00 per share, plus a contingent value right for future proceeds from ampreloxetine. Th", "url": "https://www.arthurcox.com/arthur-cox-advises-theravance-biopharma-on-its-929-million-merger-with-zymeworks/", "source_name": "Arthur Cox LLP", "published_at": "2026-07-01T08:39:40", "published_display": "01 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks agrees to buy Theravance Biopharma for $929m", "summary": "Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma for approximately $929 million (C$1.32bn). Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of net proceeds from future monetization ", "url": "https://www.pharmaceutical-technology.com/news/zymeworks-to-buy-theravance-biopharma/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-01T06:40:13", "published_display": "01 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canadian Zymeworks acquires American Theravance Biopharma for $929 million", "summary": "Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product valu", "url": "https://www.akm.ru/eng/news/canadian-zymeworks-acquires-american-theravance-biopharma-for-929-million/", "source_name": "AKM.RU", "published_at": "2026-06-30T18:43:00", "published_display": "30 Jun 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Stock Down 3% After Zymeworks Announces Buyout", "summary": "Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will rec", "url": "https://www.tradingview.com/news/zacks:bb229742f094b:0-theravance-stock-down-3-after-zymeworks-announces-buyout/", "source_name": "TradingView", "published_at": "2026-06-30T13:11:04", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion", "summary": "Zymeworks is set to acquire Theravance Biopharma in a complex deal valued at less than $1 billion, marking the end of Theravance's three-decade legacy. Despite the sale, Theravance CEO Rick Winningham expressed ongoing commitment to creating impactful medicines. The acquisition h", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/30/zymeworks-theravance-biopharma-asthma-gsk.html", "source_name": "The Business Journals", "published_at": "2026-06-30T13:11:04", "published_display": "30 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "This press release announces Zymeworks' intent to acquire Theravance Biopharma, Inc. The acquisition is expected to create a stronger combined entity with an enhanced pipeline and capabilities. Further details about the terms of the acquisition and strategic rationale are anticip", "url": "https://www.moomoo.com/news/post/72182744/press-release-zymeworks-to-acquire-theravance-biopharma-inc?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T06:10:53", "published_display": "30 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma", "summary": "This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up ", "url": "https://www.pharmexec.com/view/roundup-ipsen-acquire-kartos-therapeutics-zymeworks-theravance-biopharma", "source_name": "PharmExec.com", "published_at": "2026-06-29T14:41:13", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition", "summary": "Zymeworks announced it will acquire Theravance Biopharma for $929 million in an all-cash transaction, expected to close in the second half of 2026. This acquisition will add Yupelri, a COPD treatment, to Zymeworks' commercial portfolio, giving it a 35% share of U.S. net profits f", "url": "https://www.benzinga.com/m-a/26/06/60155321/zymeworks-targets-long-term-cash-generation-through-theravance-acquisition", "source_name": "Benzinga", "published_at": "2026-06-29T13:41:13", "published_display": "29 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks makes bold move with $929m Theravance Biopharma buy", "summary": "Zymeworks has announced a $929 million acquisition of Theravance Biopharma, marking its entry into the respiratory disease sector. The deal centers on Yupelri, an FDA-approved COPD therapy, and is financed through a non-recourse arrangement, including a $350 million note and Ther", "url": "https://www.bioxconomy.com/partnering/zymeworks-makes-bold-move-with-929m-theravance-biopharma-buy", "source_name": "BioXconomy", "published_at": "2026-06-29T13:41:13", "published_display": "29 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.", "summary": "", "url": "https://finance.yahoo.com/m/cc9004af-707b-3993-8305-4837095e5c7f/zymeworks-to-buy-theravance.html", "source_name": "Barrons.com", "published_at": "2026-06-29T12:39:00+00:00", "published_display": "29 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma in $929 Million Deal to Expand Commercial Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbzI4UUxOS0l3UjV3ZDRtY3lqUW9wZHBlZkdENjZ5WVBtNTNmVHhTNnFkVzdzcFBNOTRSOG9XOU9jaVJvak9lZG54OHlIWnRJYllmcWhKUjFlV3JaV21LdnFoZDZ6LTFNMEFnZTdNMUg1dmZPemhucEl2N2NlSzlLQlNRNWllbFZwRDAyMHg1TUd5Sjd1b2xsS3ZtbmVSUGs2T3NmckZneTc4dGd3M3RCNDhMcEExNHhZSmJmdWc3QVlZSEIyTFd2a1h4Yw?oc=5", "source_name": "citybiz", "published_at": "2026-06-29T11:50:11+00:00", "published_display": "29 Jun 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks To Buy Theravance Biopharma In $929M Deal \u2013 A Look At What This Deal Means For TBPH Shareholders", "summary": "Zymeworks is acquiring Theravance Biopharma for $929 million, with shareholders receiving $17.00 per share in cash and a contingent value right (CVR) for 80% of future net proceeds from ampreloxetine monetization. This deal, offering a 22% premium over Theravance's stock price on", "url": "https://stocktwits.com/news-articles/markets/equity/tbph-zyme-takeover-deal-929-million-ampreloxetine/cZ19JeQR7hM", "source_name": "Stocktwits", "published_at": "2026-06-29T12:41:13", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma (NASDAQ: TBPH) in $929M cash and CVR deal", "summary": "Zymeworks is set to acquire Theravance Biopharma for approximately $929 million in a cash and contingent value right (CVR) deal. Theravance shareholders will receive $17.00 per share in cash, representing a 22% premium to its March 3, 2026 closing price, plus a CVR entitling them", "url": "https://www.stocktitan.net/sec-filings/TBPH/8-k-theravance-biopharma-inc-reports-material-event-8c0ec204b88a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:27", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR", "summary": "Theravance Biopharma (TBPH) has entered into an agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right (CVR). The CVR entitles holders to additional cash based on net licensing proceeds, a $50 million milestone, and 10% of net sales for a", "url": "https://www.tradingview.com/news/tradingview:68941b86a6215:0-theravance-biopharma-to-be-acquired-by-zymeworks-for-17-per-share-plus-cvr/", "source_name": "TradingView", "published_at": "2026-06-29T10:41:13", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma for $929M", "summary": "Zymeworks has agreed to acquire Theravance Biopharma for $17 per share in cash, valuing the company at approximately $929 million. Theravance shareholders will also receive a contingent value right for 80% of net proceeds from any ampreloxetine monetization over ten years. The tr", "url": "https://grafa.com/en/news/united-states/zymeworks-acquire-theravance-biopharma-17-per-share", "source_name": "grafa.com", "published_at": "2026-06-29T10:09:44", "published_display": "29 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, approximately $929 million. The acquisition will add YUPELRI\u00ae (revefenacin), a treatment for COPD, to Zymeworks' portfolio, anticipated to generate around $60 million in an", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318760/0/en/zymeworks-to-acquire-theravance-biopharma-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T09:41:13", "published_display": "29 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks expands beyond cancer with $929 million Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYl96eGp0T2pxeVRxWWpUOVhYNG14TnNURmlxc2d4UW9NcTZsT001b2ttRzBkNXVyaXFYeC1kaFQzRE9Jb1BtWldvZGZJMTJJUk9PTUVmbFFkNFlsdHBHLWp4WXl5Ujh3dUdBSElHangzRFZESHBUeVdjRV9lUS1vSmxWOGFaSGpWYkJ4Y09LaldKSHpvaTJqdHBndHh0ZGJ5SW9kOFBTSGdTc2E2?oc=5", "source_name": "Reuters", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley reiterates buy on Zymeworks stock after Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNRXhOUDk1eFFKRGswNTdhS2dWUC0tUjVWTHR0T2E5NjUxSEhVbXJISF9jVlM5RjZZcC1HNGRoXy1aOE1od29ZbHFZbnl3bUN2UEx0S1plV3lRbEZEUVIwUFpnRlh3RVZzM09pZjdob3JQelI5UjFhRmcxYWd0d2M1X0lYMHhMSzlqZmx4Um5lSnJhSnFRTDctR3VRRlZ0d0syQnJmWjFJZlhiVFRBcXhmNmFwNnROMVR2WGVpR29OU3hPQnkwQ01IajN3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma, Inc.(NasdaqGM:TBPH) added to Russell 2000 Value-Defensive Index", "summary": "Theravance Biopharma, Inc. (NasdaqGM:TBPH) has been added to the Russell 2000 Value-Defensive Index. This news follows a series of recent announcements for the company, including its addition to the Russell 2000 Growth-Defensive Index, first-quarter earnings results, and various ", "url": "https://www.marketscreener.com/news/theravance-biopharma-inc-nasdaqgm-tbph-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cf726", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:40:02", "published_display": "29 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Theravance Biopharma, Inc. (NASDAQ:TBPH). It briefly presents this data within the context of the company's financial information on TradingView. The content primarily provides navigation and structural ele", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:14", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article provides the \"Price to book forward\" value for Theravance Biopharma, Inc. (NASDAQ: TBPH). It indicates a specific period and market data source, highlighting it as financial information for investors. The article is a snippet of financial data from TradingView, focus", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:29", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article provides financial data for Theravance Biopharma, Inc. (NASDAQ: TBPH), specifically its enterprise value to revenue forward metric. The content appears to be a snapshot from a financial platform like TradingView, displaying the company's ticker, market status, and a ", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:55", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Inc Actuals & Estimates (NASDAQ:TBPH)", "summary": "This article provides an overview of Theravance Biopharma, Inc. (NASDAQ: TBPH) financial actuals, analyst estimates, and stock performance data. It covers current stock price, market capitalization, historical highs and lows, future earnings expectations, and key financial metric", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:54", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) sets exit terms for Ireland SVP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRExwam9jZkhLLWpVV1ZfT1hCa2lvbjE3aWk5MzhQUG1VWU5pOVRHWmUzWWdlM1lWTzZSbWNMR054TzZXVTBkOXhkNWc0NW5lN0tXNlE5cTFnaFJUQ1l1SFVvT0FUUG5iQXFLMnlQWkR3b3JXMjhNbjNTWko0T1ltc0pvRHJfbEpKbE9aQThISDd5bkJjdWdXdkY4MlJLZXEzUlJqSXl0ODV0VVBUOGJCVXdENA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) SVP awarded 18,750 Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTnRlYzA0Y3VhMlpLTVRyeHlrNDlxMzUwNlVFX0QzZ1RuTTNfZDQ1VFlleE9id3FLeldzUGhhVDdUelFQUWFOZWZuV2xqMjBRVUhEaTZaRG1qVzZ2Wi1SZFFGbUFucWpMSmxUWjBHSWlfSEpEeDhxend1ejM0ZUZsNlFjT0IxY0s3Wld2cl9yNE5kRnlNRW9GbnNpTHVlT3FfQjE2dEJKVk5odHBIRFZSa0owTnB5M3R2N2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (TBPH) SVP Rhonda Farnum sells 13,314 shares at ~$16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOVJaVFRFUHpxUk1sTnJDLTMwRHVEdDdmeFVfRHpVeU9EQW1wSF9IUGltRWJhTjZTbDZSekVhelZkNm1JOTdpTkhxM0x5cWloOHZnaWV1UjBSOUg2SEFOS3BSV3E5Um5xWTBuYzdxdG9LeEhQWUtVU0dSLVZhTmsyNDNveDJLZ0tiOG9xUHBNS0xUQUdpeW1MXzdkaWYzTU1XdkI2M2pxNU5oekpPUWVETmR4SEpFaEFhLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Theravance Biopharma (TBPH) receives new share and option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQa0ZvZnA1SWFpT0ZyX0JDeGhwb0ZnUmRHREtsRnYyeU1KcGNLd1RTWk1oTTlxVFFMdHI4aU9ISDJwUU1tWXdlYTNtU3o4dERHb3NUSzVVaDNqUGo3eXU4UTBneWRSTlVBdVplVmxvM3hiaFpJWGRhMkp2N2Vjams1LVZmMDNNQUhzMnV0XzlnSDJ2MHYyRkNMcDNOQ21YTXlyenFJc0MtSGljYmtDaGZiN1ZvbTRTODBBWkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) director granted shares and 13,398-share option", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQ0VITGt1T0dTMWxRbEozQ2hJTExlSmlsemwyQmlocHduYTBrc2xQeDFwaXdJWl8weGVDSkdQSkY2MWJLN2l6Mlo1cjdpenBxVmpoOGU2OS02eXE3VEJ1RWJvRnRXSlVjejNwNmFhRFQ3dXZyTGRMY2NRZDBDaXB2TWstU2tWTGhERmFJWmU1dzM1OHB5RnBXQTVUZEg2OGd6QjZ5SmNMWTB6WFp3NXJOc2hpeGx1OU9CQUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Dean J. Mitchell granted shares and options at Theravance (NASDAQ: TBPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQklaTTFSWUVKcHRpOUlJdERTZEVJblJ3WFRVWXdpellGNXhyQ0NVNTdVU3UwY3BtcXlDd05FNzN2UVRuMmlNRkhPZE5ha0k1b0ZMU0VXRXBhaVpzNndpMHg0SnNBbDhxZ0M3Nkd4c1FyVlhCSnplSWpITlF3YjI1T0ZDUk9xRTF3MGJwdmhvU0podVRSSW5UcEhGWWJuUTBtWGJYQWpZeXA5WTBDMHdXUkFTa0d2a2JZaEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNdTlRYjB0eER5QU5XZFBkSHBQcWtvVEhXV0ctSDUtZ1B3cEd0WFBqejV2a1NWOXhFa01UcjY1eDk2RGNPQXAwMFg1X0VyeG1LY29lMWtZVDQ4c2pSbDRuOXZBXzZLVkk0TG1CRDF4TnM3TmdqU3FGY0c2anJxMngwNXNqWUpzX210dy1uSW5HX29GM1p6N1ljdHpkVl9QYVpxSjBNOXNGWUdBMzkxczN6alcyOGdDd1VDTnctZmlBMXRFbmpVaWdXYmRTTTItSEVnbXE1cDZmUTdEci1BQVM0OUhDYmxpSU5BemZz?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbjVzVWJnellWWVhxR0kxejlJSS1SLVlHTXJhWlBXTVBBdWkxcEY2TGw3N3JQUUx6MF84Q0lsVjhyVDJmanZlOWlkLXB0UndzMDZwbTVnREZuRUZ4NHM0YS1FSG81Vld2azM3VkpzeVhRUW9zMGJTQjFyWU9abmtxSTJfWlhoV21xWDh6REllYngxUlZMekxFMjg5Z1JlV2JnQmx5LU0ybGdXUmowUDc1b0xuWnpiUlBm?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOTkU3ckk5a0s4M29YYU1qQ0JJa3pHR1I4NHJRWTN6NVZKbU5NMXlqVnNHWUpFSHphblpBcE9TTDNETzA3ejJfMEpJZEVtZ09TQkVabWhhSDNRU1luXzZYSnZzQzFxQW9SM09BWFF3YkpkbmlzN2NFY0txeHZ2WjcycFNxUzhkS3RaSGhwRFZqeTFibndmNlNfOWx0OEg?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQQ21yR2FXekZDT2xKZW5hSEd0c0xPeENFY2FmcVJfUVEzdlNnV2tPTHRiQXQ2dFB1WGhORDUzdGdFUkxRQ1dScXNtdnpBS3lrek5McFBuTGhiay00a1ptWlZUOWtoNFhYSUIxRXhvbV9oY1ZpU1pRM3lDVjR6ekxGUDU5ejhCQUdOVm1QUWhqYlVIal9paXRGWDdwdS0?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN195ZDgzSVQ3Q0lYVThUWXpzelJZMzkxc3p6YXluM2dWUUVGZG5YYVhnUUJUVGNpb1Znbmd2YW9ZU0ZkR0hRNXNaUWlUQ01xTHI0YmpnMk9udjVKMXJNT1ZNWmh6anJCaHJkSE0zOTNUdWtBc0NfRmx3Q3F5N3lESEhRWFJMcmZPUURENHJMLTlHQlpTN3BCMm9LamFaVFRLLThHMDUySTQ0dw?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPNVdxUW9qbll4NzZiZU1kUnp5eVFfY29HR0p5c2ZYaFZ4SkMwWkt6MU8yc2dUdGY4cUktM05VYU9RQVlYTlJGRk5xTlExVS1hb3BsLTRHRWt4NmRGWldzZnR0eGZIV1BldWhudXhBb2owbjd5SUVUZEQwVlFZMldEa1phbHBZcWJTa2ow?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxOUk1GWDRfVzN4aFcxUjRkQjNkS1Q1VVFVbzJZUXdrZmJYZGJwU0ZjdVlEUGJqSmpBT0RzM2ZRWmkwc3NYaGFpQ25ycURfeVhQdFdQakdFZkdqakk3WHFLS0p6b1NWQXFnUElUQk5McDAwam5RRHFMWE1WRTJpNTAwOU1PQlZXZGlIT09TRnRrclFQYXh6SVBFNFZrMEdjV2dyekJnQlU2MHJxZU52dmFudlBGVVpfR0VyZXBsbWw3R3BKREoxMmotVHVJRm9hbkVkVy1tZERsdTdZcmFEWGs4TVM2WHdFQUNHWVVBV2pJTW1xcEE5aHlsZUd6ODBlbzBReUViaEJSOVFwQTdzS1EtM254ZVI2bTZuekZ2RG9MX2lDdFN2NXBhenhpTk5KU2xYenc?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQmMtS0NXU0VsYW9BNEVsalhWOC14c3d4bURHc3plc19tV0RZM3BaQ2ZwWXdpWnB3QndtUFJNRGFweTNiMjJrQ1FiQnFxM1F0N0JaUXlHWklBeV9INk1LVTl1YjM0VUZkY2cyMVQ5QlFEX0NGZDNJa0Y3NEJ2WklrZ00zazVxcVBYZkdZMW9qTTlkT3EwYUdtZ2M1THhXdGJOLVdlNVpabWdZdnRWVWxfanJnakNnRm1UMlhoekdQQm9sRmEtdnZvRDRxMkloa3ZHNXdTUFdtSmpaQjlMQ2tseUgzUHVWUkJQbXpV?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVFBhZjRNemlfWVR1VTFBY2I2QXpSTGFZbC1rZlltZGNJQkdiS3pMMDl2N1hmdm5tSTRKM0w0M3RfM1ViUDM2QjAyaVdQNW9WVkFMU0dFdVllMlpobWpLanRMcGxwZFRGbUdNMDVmYnlZeTRlZl9ER3VTZkRIREFZTFNxTzhUczR1WVFON1VONDR2NndjdzJLTFpWbG55VEJsZzV1N0N3QnF0YVIyR0F2dkdaZkNKWHFyVTlHR3NRQzFEQkd2RXlXdXlPOTdaVXZ4?oc=5", "source_name": "Investing.com", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has increased its price target for Theravance Biopharma (TBPH) shares to $17.00, up from the previous target of $15.00. This adjustment reflects an updated outlook on the company's valuation.", "url": "https://www.moomoo.com/news/post/72584556/theravance-biopharma-price-target-raised-to-17-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-07T17:10:51", "published_display": "07 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future", "summary": "Zymeworks is strategically pivoting beyond its oncology focus with the $929 million acquisition of Theravance Biopharma, gaining the FDA-approved COPD therapy, Yupelri. This move aligns with current biopharma M&A trends emphasizing de-risked, cash-generating assets to address pat", "url": "https://www.kavout.com/market-lens/zymeworks-929-million-pivot-how-a-copd-acquisition-redefines-its-future", "source_name": "Kavout | AI", "published_at": "2026-07-06T08:41:47", "published_display": "06 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Options", "summary": "This article provides a detailed financial overview of Theravance Biopharma Inc. (TBPH), including its latest stock performance, market capitalization, key financial ratios, and insider/institutional ownership data. It presents various metrics such as P/E, sales growth, profit ma", "url": "https://finviz.com/stock?t=TBPH&ty=oc&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-06T08:41:47", "published_display": "06 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI\u00ae extending generic availability to 2", "url": "https://www.stocktitan.net/sec-filings/TBPH/page-3.html", "source_name": "Stock Titan", "published_at": "2026-07-04T02:40:15", "published_display": "04 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Short Interest", "summary": "This article provides a detailed overview of Theravance Biopharma Inc (TBPH) stock, focusing on various financial metrics, short interest data, and performance indicators. It includes information on the company's market capitalization, income, sales, P/E ratio, short interest per", "url": "https://finviz.com/stock?t=TBPH&ta=1&p=d&ty=si&b=1", "source_name": "Finviz", "published_at": "2026-07-02T20:11:25", "published_display": "02 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TBPH - Theravance Biopharma Inc Latest SEC Filings", "summary": "This article provides detailed financial data and performance metrics for Theravance Biopharma Inc (TBPH), including its latest stock close, market capitalization, income, sales, and various financial ratios. It also outlines insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=TBPH&ty=lf&page=36", "source_name": "Finviz", "published_at": "2026-07-02T19:40:54", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT", "summary": "Theravance Biopharma has announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, totaling approximately $929 million in equity value. In addition to the cash payment, Theravance Biopharma shareholders will receive a contingent value right (CVR) ", "url": "https://finance.yahoo.com/healthcare/articles/theravance-biopharma-enters-definitive-agreement-100000053.html", "source_name": "Market source", "published_at": "2026-07-02T09:41:16", "published_display": "02 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/theravance-biopharma-insider-sold-shares-082329638.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:23:29+00:00", "published_display": "02 Jul 2026 08:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales", "summary": "Funds associated with Eli Samaha, managed by Madison Avenue Partners, LP, have significantly reduced their stake in Theravance Biopharma (TBPH) through open-market sales. Over three days, the funds sold a total of 336,697 shares at weighted average prices around $17 per share. De", "url": "https://www.stocktitan.net/sec-filings/TBPH/form-4-theravance-biopharma-inc-insider-trading-activity-7e4ffd5226ae.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:40:13", "published_display": "01 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma in deal worth $929m", "summary": "Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition a", "url": "https://pmlive.com/pharma_news/zymeworks-to-acquire-theravance-biopharma-in-deal-worth-929m/", "source_name": "PMLiVE", "published_at": "2026-07-01T09:39:40", "published_display": "01 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks", "summary": "Arthur Cox advised Theravance Biopharma, Inc. on its definitive agreement to be acquired by Zymeworks Inc. for approximately US$929 million. The transaction values Theravance Biopharma at US$17.00 per share, plus a contingent value right for future proceeds from ampreloxetine. Th", "url": "https://www.arthurcox.com/arthur-cox-advises-theravance-biopharma-on-its-929-million-merger-with-zymeworks/", "source_name": "Arthur Cox LLP", "published_at": "2026-07-01T08:39:40", "published_display": "01 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks agrees to buy Theravance Biopharma for $929m", "summary": "Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma for approximately $929 million (C$1.32bn). Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of net proceeds from future monetization ", "url": "https://www.pharmaceutical-technology.com/news/zymeworks-to-buy-theravance-biopharma/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-01T06:40:13", "published_display": "01 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canadian Zymeworks acquires American Theravance Biopharma for $929 million", "summary": "Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product valu", "url": "https://www.akm.ru/eng/news/canadian-zymeworks-acquires-american-theravance-biopharma-for-929-million/", "source_name": "AKM.RU", "published_at": "2026-06-30T18:43:00", "published_display": "30 Jun 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Stock Down 3% After Zymeworks Announces Buyout", "summary": "Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will rec", "url": "https://www.tradingview.com/news/zacks:bb229742f094b:0-theravance-stock-down-3-after-zymeworks-announces-buyout/", "source_name": "TradingView", "published_at": "2026-06-30T13:11:04", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion", "summary": "Zymeworks is set to acquire Theravance Biopharma in a complex deal valued at less than $1 billion, marking the end of Theravance's three-decade legacy. Despite the sale, Theravance CEO Rick Winningham expressed ongoing commitment to creating impactful medicines. The acquisition h", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/30/zymeworks-theravance-biopharma-asthma-gsk.html", "source_name": "The Business Journals", "published_at": "2026-06-30T13:11:04", "published_display": "30 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "This press release announces Zymeworks' intent to acquire Theravance Biopharma, Inc. The acquisition is expected to create a stronger combined entity with an enhanced pipeline and capabilities. Further details about the terms of the acquisition and strategic rationale are anticip", "url": "https://www.moomoo.com/news/post/72182744/press-release-zymeworks-to-acquire-theravance-biopharma-inc?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T06:10:53", "published_display": "30 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma", "summary": "This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up ", "url": "https://www.pharmexec.com/view/roundup-ipsen-acquire-kartos-therapeutics-zymeworks-theravance-biopharma", "source_name": "PharmExec.com", "published_at": "2026-06-29T14:41:13", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition", "summary": "Zymeworks announced it will acquire Theravance Biopharma for $929 million in an all-cash transaction, expected to close in the second half of 2026. This acquisition will add Yupelri, a COPD treatment, to Zymeworks' commercial portfolio, giving it a 35% share of U.S. net profits f", "url": "https://www.benzinga.com/m-a/26/06/60155321/zymeworks-targets-long-term-cash-generation-through-theravance-acquisition", "source_name": "Benzinga", "published_at": "2026-06-29T13:41:13", "published_display": "29 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks makes bold move with $929m Theravance Biopharma buy", "summary": "Zymeworks has announced a $929 million acquisition of Theravance Biopharma, marking its entry into the respiratory disease sector. The deal centers on Yupelri, an FDA-approved COPD therapy, and is financed through a non-recourse arrangement, including a $350 million note and Ther", "url": "https://www.bioxconomy.com/partnering/zymeworks-makes-bold-move-with-929m-theravance-biopharma-buy", "source_name": "BioXconomy", "published_at": "2026-06-29T13:41:13", "published_display": "29 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.", "summary": "", "url": "https://finance.yahoo.com/m/cc9004af-707b-3993-8305-4837095e5c7f/zymeworks-to-buy-theravance.html", "source_name": "Barrons.com", "published_at": "2026-06-29T12:39:00+00:00", "published_display": "29 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma in $929 Million Deal to Expand Commercial Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbzI4UUxOS0l3UjV3ZDRtY3lqUW9wZHBlZkdENjZ5WVBtNTNmVHhTNnFkVzdzcFBNOTRSOG9XOU9jaVJvak9lZG54OHlIWnRJYllmcWhKUjFlV3JaV21LdnFoZDZ6LTFNMEFnZTdNMUg1dmZPemhucEl2N2NlSzlLQlNRNWllbFZwRDAyMHg1TUd5Sjd1b2xsS3ZtbmVSUGs2T3NmckZneTc4dGd3M3RCNDhMcEExNHhZSmJmdWc3QVlZSEIyTFd2a1h4Yw?oc=5", "source_name": "citybiz", "published_at": "2026-06-29T11:50:11+00:00", "published_display": "29 Jun 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks To Buy Theravance Biopharma In $929M Deal \u2013 A Look At What This Deal Means For TBPH Shareholders", "summary": "Zymeworks is acquiring Theravance Biopharma for $929 million, with shareholders receiving $17.00 per share in cash and a contingent value right (CVR) for 80% of future net proceeds from ampreloxetine monetization. This deal, offering a 22% premium over Theravance's stock price on", "url": "https://stocktwits.com/news-articles/markets/equity/tbph-zyme-takeover-deal-929-million-ampreloxetine/cZ19JeQR7hM", "source_name": "Stocktwits", "published_at": "2026-06-29T12:41:13", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma (NASDAQ: TBPH) in $929M cash and CVR deal", "summary": "Zymeworks is set to acquire Theravance Biopharma for approximately $929 million in a cash and contingent value right (CVR) deal. Theravance shareholders will receive $17.00 per share in cash, representing a 22% premium to its March 3, 2026 closing price, plus a CVR entitling them", "url": "https://www.stocktitan.net/sec-filings/TBPH/8-k-theravance-biopharma-inc-reports-material-event-8c0ec204b88a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:27", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR", "summary": "Theravance Biopharma (TBPH) has entered into an agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right (CVR). The CVR entitles holders to additional cash based on net licensing proceeds, a $50 million milestone, and 10% of net sales for a", "url": "https://www.tradingview.com/news/tradingview:68941b86a6215:0-theravance-biopharma-to-be-acquired-by-zymeworks-for-17-per-share-plus-cvr/", "source_name": "TradingView", "published_at": "2026-06-29T10:41:13", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to acquire Theravance Biopharma for $929M", "summary": "Zymeworks has agreed to acquire Theravance Biopharma for $17 per share in cash, valuing the company at approximately $929 million. Theravance shareholders will also receive a contingent value right for 80% of net proceeds from any ampreloxetine monetization over ten years. The tr", "url": "https://grafa.com/en/news/united-states/zymeworks-acquire-theravance-biopharma-17-per-share", "source_name": "grafa.com", "published_at": "2026-06-29T10:09:44", "published_display": "29 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, approximately $929 million. The acquisition will add YUPELRI\u00ae (revefenacin), a treatment for COPD, to Zymeworks' portfolio, anticipated to generate around $60 million in an", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318760/0/en/zymeworks-to-acquire-theravance-biopharma-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T09:41:13", "published_display": "29 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks expands beyond cancer with $929 million Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYl96eGp0T2pxeVRxWWpUOVhYNG14TnNURmlxc2d4UW9NcTZsT001b2ttRzBkNXVyaXFYeC1kaFQzRE9Jb1BtWldvZGZJMTJJUk9PTUVmbFFkNFlsdHBHLWp4WXl5Ujh3dUdBSElHangzRFZESHBUeVdjRV9lUS1vSmxWOGFaSGpWYkJ4Y09LaldKSHpvaTJqdHBndHh0ZGJ5SW9kOFBTSGdTc2E2?oc=5", "source_name": "Reuters", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley reiterates buy on Zymeworks stock after Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNRXhOUDk1eFFKRGswNTdhS2dWUC0tUjVWTHR0T2E5NjUxSEhVbXJISF9jVlM5RjZZcC1HNGRoXy1aOE1od29ZbHFZbnl3bUN2UEx0S1plV3lRbEZEUVIwUFpnRlh3RVZzM09pZjdob3JQelI5UjFhRmcxYWd0d2M1X0lYMHhMSzlqZmx4Um5lSnJhSnFRTDctR3VRRlZ0d0syQnJmWjFJZlhiVFRBcXhmNmFwNnROMVR2WGVpR29OU3hPQnkwQ01IajN3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma, Inc.(NasdaqGM:TBPH) added to Russell 2000 Value-Defensive Index", "summary": "Theravance Biopharma, Inc. (NasdaqGM:TBPH) has been added to the Russell 2000 Value-Defensive Index. This news follows a series of recent announcements for the company, including its addition to the Russell 2000 Growth-Defensive Index, first-quarter earnings results, and various ", "url": "https://www.marketscreener.com/news/theravance-biopharma-inc-nasdaqgm-tbph-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cf726", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:40:02", "published_display": "29 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Theravance Biopharma, Inc. (NASDAQ:TBPH). It briefly presents this data within the context of the company's financial information on TradingView. The content primarily provides navigation and structural ele", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:14", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article provides the \"Price to book forward\" value for Theravance Biopharma, Inc. (NASDAQ: TBPH). It indicates a specific period and market data source, highlighting it as financial information for investors. The article is a snippet of financial data from TradingView, focus", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:29", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Theravance Biopharma, Inc. \u2013 NASDAQ:TBPH", "summary": "This article provides financial data for Theravance Biopharma, Inc. (NASDAQ: TBPH), specifically its enterprise value to revenue forward metric. The content appears to be a snapshot from a financial platform like TradingView, displaying the company's ticker, market status, and a ", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:55", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Inc Actuals & Estimates (NASDAQ:TBPH)", "summary": "This article provides an overview of Theravance Biopharma, Inc. (NASDAQ: TBPH) financial actuals, analyst estimates, and stock performance data. It covers current stock price, market capitalization, historical highs and lows, future earnings expectations, and key financial metric", "url": "https://www.tradingview.com/symbols/NASDAQ-TBPH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:54", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) sets exit terms for Ireland SVP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRExwam9jZkhLLWpVV1ZfT1hCa2lvbjE3aWk5MzhQUG1VWU5pOVRHWmUzWWdlM1lWTzZSbWNMR054TzZXVTBkOXhkNWc0NW5lN0tXNlE5cTFnaFJUQ1l1SFVvT0FUUG5iQXFLMnlQWkR3b3JXMjhNbjNTWko0T1ltc0pvRHJfbEpKbE9aQThISDd5bkJjdWdXdkY4MlJLZXEzUlJqSXl0ODV0VVBUOGJCVXdENA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) SVP awarded 18,750 Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTnRlYzA0Y3VhMlpLTVRyeHlrNDlxMzUwNlVFX0QzZ1RuTTNfZDQ1VFlleE9id3FLeldzUGhhVDdUelFQUWFOZWZuV2xqMjBRVUhEaTZaRG1qVzZ2Wi1SZFFGbUFucWpMSmxUWjBHSWlfSEpEeDhxend1ejM0ZUZsNlFjT0IxY0s3Wld2cl9yNE5kRnlNRW9GbnNpTHVlT3FfQjE2dEJKVk5odHBIRFZSa0owTnB5M3R2N2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (TBPH) SVP Rhonda Farnum sells 13,314 shares at ~$16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOVJaVFRFUHpxUk1sTnJDLTMwRHVEdDdmeFVfRHpVeU9EQW1wSF9IUGltRWJhTjZTbDZSekVhelZkNm1JOTdpTkhxM0x5cWloOHZnaWV1UjBSOUg2SEFOS3BSV3E5Um5xWTBuYzdxdG9LeEhQWUtVU0dSLVZhTmsyNDNveDJLZ0tiOG9xUHBNS0xUQUdpeW1MXzdkaWYzTU1XdkI2M2pxNU5oekpPUWVETmR4SEpFaEFhLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Theravance Biopharma (TBPH) receives new share and option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQa0ZvZnA1SWFpT0ZyX0JDeGhwb0ZnUmRHREtsRnYyeU1KcGNLd1RTWk1oTTlxVFFMdHI4aU9ISDJwUU1tWXdlYTNtU3o4dERHb3NUSzVVaDNqUGo3eXU4UTBneWRSTlVBdVplVmxvM3hiaFpJWGRhMkp2N2Vjams1LVZmMDNNQUhzMnV0XzlnSDJ2MHYyRkNMcDNOQ21YTXlyenFJc0MtSGljYmtDaGZiN1ZvbTRTODBBWkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (NASDAQ: TBPH) director granted shares and 13,398-share option", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQ0VITGt1T0dTMWxRbEozQ2hJTExlSmlsemwyQmlocHduYTBrc2xQeDFwaXdJWl8weGVDSkdQSkY2MWJLN2l6Mlo1cjdpenBxVmpoOGU2OS02eXE3VEJ1RWJvRnRXSlVjejNwNmFhRFQ3dXZyTGRMY2NRZDBDaXB2TWstU2tWTGhERmFJWmU1dzM1OHB5RnBXQTVUZEg2OGd6QjZ5SmNMWTB6WFp3NXJOc2hpeGx1OU9CQUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Dean J. Mitchell granted shares and options at Theravance (NASDAQ: TBPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQklaTTFSWUVKcHRpOUlJdERTZEVJblJ3WFRVWXdpellGNXhyQ0NVNTdVU3UwY3BtcXlDd05FNzN2UVRuMmlNRkhPZE5ha0k1b0ZMU0VXRXBhaVpzNndpMHg0SnNBbDhxZ0M3Nkd4c1FyVlhCSnplSWpITlF3YjI1T0ZDUk9xRTF3MGJwdmhvU0podVRSSW5UcEhGWWJuUTBtWGJYQWpZeXA5WTBDMHdXUkFTa0d2a2JZaEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNdTlRYjB0eER5QU5XZFBkSHBQcWtvVEhXV0ctSDUtZ1B3cEd0WFBqejV2a1NWOXhFa01UcjY1eDk2RGNPQXAwMFg1X0VyeG1LY29lMWtZVDQ4c2pSbDRuOXZBXzZLVkk0TG1CRDF4TnM3TmdqU3FGY0c2anJxMngwNXNqWUpzX210dy1uSW5HX29GM1p6N1ljdHpkVl9QYVpxSjBNOXNGWUdBMzkxczN6alcyOGdDd1VDTnctZmlBMXRFbmpVaWdXYmRTTTItSEVnbXE1cDZmUTdEci1BQVM0OUhDYmxpSU5BemZz?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbjVzVWJnellWWVhxR0kxejlJSS1SLVlHTXJhWlBXTVBBdWkxcEY2TGw3N3JQUUx6MF84Q0lsVjhyVDJmanZlOWlkLXB0UndzMDZwbTVnREZuRUZ4NHM0YS1FSG81Vld2azM3VkpzeVhRUW9zMGJTQjFyWU9abmtxSTJfWlhoV21xWDh6REllYngxUlZMekxFMjg5Z1JlV2JnQmx5LU0ybGdXUmowUDc1b0xuWnpiUlBm?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOTkU3ckk5a0s4M29YYU1qQ0JJa3pHR1I4NHJRWTN6NVZKbU5NMXlqVnNHWUpFSHphblpBcE9TTDNETzA3ejJfMEpJZEVtZ09TQkVabWhhSDNRU1luXzZYSnZzQzFxQW9SM09BWFF3YkpkbmlzN2NFY0txeHZ2WjcycFNxUzhkS3RaSGhwRFZqeTFibndmNlNfOWx0OEg?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQQ21yR2FXekZDT2xKZW5hSEd0c0xPeENFY2FmcVJfUVEzdlNnV2tPTHRiQXQ2dFB1WGhORDUzdGdFUkxRQ1dScXNtdnpBS3lrek5McFBuTGhiay00a1ptWlZUOWtoNFhYSUIxRXhvbV9oY1ZpU1pRM3lDVjR6ekxGUDU5ejhCQUdOVm1QUWhqYlVIal9paXRGWDdwdS0?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN195ZDgzSVQ3Q0lYVThUWXpzelJZMzkxc3p6YXluM2dWUUVGZG5YYVhnUUJUVGNpb1Znbmd2YW9ZU0ZkR0hRNXNaUWlUQ01xTHI0YmpnMk9udjVKMXJNT1ZNWmh6anJCaHJkSE0zOTNUdWtBc0NfRmx3Q3F5N3lESEhRWFJMcmZPUURENHJMLTlHQlpTN3BCMm9LamFaVFRLLThHMDUySTQ0dw?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPNVdxUW9qbll4NzZiZU1kUnp5eVFfY29HR0p5c2ZYaFZ4SkMwWkt6MU8yc2dUdGY4cUktM05VYU9RQVlYTlJGRk5xTlExVS1hb3BsLTRHRWt4NmRGWldzZnR0eGZIV1BldWhudXhBb2owbjd5SUVUZEQwVlFZMldEa1phbHBZcWJTa2ow?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxOUk1GWDRfVzN4aFcxUjRkQjNkS1Q1VVFVbzJZUXdrZmJYZGJwU0ZjdVlEUGJqSmpBT0RzM2ZRWmkwc3NYaGFpQ25ycURfeVhQdFdQakdFZkdqakk3WHFLS0p6b1NWQXFnUElUQk5McDAwam5RRHFMWE1WRTJpNTAwOU1PQlZXZGlIT09TRnRrclFQYXh6SVBFNFZrMEdjV2dyekJnQlU2MHJxZU52dmFudlBGVVpfR0VyZXBsbWw3R3BKREoxMmotVHVJRm9hbkVkVy1tZERsdTdZcmFEWGs4TVM2WHdFQUNHWVVBV2pJTW1xcEE5aHlsZUd6ODBlbzBReUViaEJSOVFwQTdzS1EtM254ZVI2bTZuekZ2RG9MX2lDdFN2NXBhenhpTk5KU2xYenc?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQmMtS0NXU0VsYW9BNEVsalhWOC14c3d4bURHc3plc19tV0RZM3BaQ2ZwWXdpWnB3QndtUFJNRGFweTNiMjJrQ1FiQnFxM1F0N0JaUXlHWklBeV9INk1LVTl1YjM0VUZkY2cyMVQ5QlFEX0NGZDNJa0Y3NEJ2WklrZ00zazVxcVBYZkdZMW9qTTlkT3EwYUdtZ2M1THhXdGJOLVdlNVpabWdZdnRWVWxfanJnakNnRm1UMlhoekdQQm9sRmEtdnZvRDRxMkloa3ZHNXdTUFdtSmpaQjlMQ2tseUgzUHVWUkJQbXpV?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVFBhZjRNemlfWVR1VTFBY2I2QXpSTGFZbC1rZlltZGNJQkdiS3pMMDl2N1hmdm5tSTRKM0w0M3RfM1ViUDM2QjAyaVdQNW9WVkFMU0dFdVllMlpobWpLanRMcGxwZFRGbUdNMDVmYnlZeTRlZl9ER3VTZkRIREFZTFNxTzhUczR1WVFON1VONDR2NndjdzJLTFpWbG55VEJsZzV1N0N3QnF0YVIyR0F2dkdaZkNKWHFyVTlHR3NRQzFEQkd2RXlXdXlPOTdaVXZ4?oc=5", "source_name": "Investing.com", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 57, "sentiment_summary": {"positive": 20, "negative": 3, "neutral": 34, "score": 57, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 71, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 10.25, "count": 18}, {"event": "general", "label": "Market update", "weight": 10.05, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 16.93, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": 1.7, "twelve_week_move": -1.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.646747, "market_dynamics_buy_signal": false, "relative_strength": -9.85257, "fair_value_gap": 45.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 60.9976, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +1.7% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "Finviz", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 18}, {"label": "Market update", "count": 17}, {"label": "Earnings", "count": 15}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +1.7% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co."}], "updated_at": "2026-07-18T08:31:54.026358+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}